Thus, based on the latest literature data and results obtained from the present study, it can be concluded that targeting of the components of the PERK-dependent UPR signaling pathway via small-molecule PERK inhibitors, such as LDN-0060609, may contribute to the development of novel, innovative treatment strategies against POAG. Here, EIF2AK3 is linked to open-angle glaucoma.